What Vaxxinity does

Vaxxinity is a clinical-stage biotechnology company developing a pipeline of synthetic peptide vaccines based on its proprietary Active Immunotherapy Medicine (AIM) platform. The platform uses synthetic peptides designed to mimic biological epitopes, selectively activating the immune system to overcome immune tolerance and stimulating the body to produce its own therapeutic antibodies. The company targets three primary disease areas: neurodegenerative diseases (Alzheimer's via UB-311 and Parkinson's via UB-312), infectious disease (COVID-19 booster UB-612, which completed Phase 3), and cardiovascular disease (anti-PCSK9 cholesterol vaccine VXX-401, in preclinical development). AIM-based products are differentiated by conventional 2-8°C cold chain storage requirements, eliminating the need for frozen infrastructure needed by mRNA vaccines, and by synthetic, scalable, low-cost manufacturing.

The company's pipeline has accumulated 10 completed human clinical trials, multiple peer-reviewed publications in Nature Medicine, The Lancet, and Movement Disorders journals, and a Phase 3 success for UB-612. It has established research partnerships with CEPI, the University of Florida's Center for Translational Research in Neurodegenerative Disease, and the University of Central Florida, plus a Frontier Exploration Laboratory in Florida. Revenue is effectively zero: no products are commercialized, pricing is not publicly disclosed, and the company is funded through grants and prior capital rather than product sales. In April 2024, Vaxxinity announced its intention to voluntarily delist from Nasdaq and deregister its Class A common stock, suspending public reporting obligations.

Name

Vaxxinity

Legal name

Vaxxinity, Inc.

Website

https://vaxxinity.com

Company type

Public

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Vaxxinity is a clinical-stage biotechnology company developing synthetic peptide vaccines using its proprietary AIM platform to treat and prevent infectious, neurodegenerative, and cardiovascular diseases, with all pipeline assets in clinical or preclinical development.

Ownership category

akta.pro rank

Product category

Therapeutic Vaccines / Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Therapeutic Vaccines (e.g., Cancer/Chronic Infection) (HLAIAEAG)

akta.pro secondary industries

Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB), Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH), Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)

Keywords

• Synthetic peptide vaccines
• Active immunotherapy
• Neurodegenerative disease therapeutics
• Preventive vaccines
• Biopharmaceutical research

Headquarters

HQ city

Dallas

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Distribution channels1 record

Marketing channels3 records

Core offering

Vaxxinity develops a pipeline of synthetic peptide-based active immunotherapy vaccine candidates built on its proprietary AIM (Active Immunotherapy Medicine) platform. The pipeline targets chronic and infectious diseases — including Alzheimer's (UB-311), Parkinson's (UB-312), COVID-19 (UB-612), and elevated LDL cholesterol (VXX-401) — by stimulating the patient's own immune system to produce therapeutic antibodies. Products are designed to be low-cost, scalable, and storable at conventional 2–8°C cold chain temperatures.

Product overview

Vaxxinity is developing a pipeline of active immunotherapies based on its proprietary AIM (Active Immunotherapy Medicine) platform. The platform uses synthetic peptides to convert the body into its own antibody factory. The product portfolio includes UB-612 (COVID-19 booster vaccine), UB-311 (Alzheimer's disease vaccine), UB-312 (Parkinson's disease vaccine), and VXX-401 (cholesterol-lowering vaccine), all designed to stimulate the immune system to produce therapeutic antibodies against specific disease targets.

Differentiator

Problem solved

Functional benefit

Products and services

• UB-612 (COVID-19 Booster Vaccine) Multitope protein-peptide COVID-19 booster vaccine designed to be effective against emerging SARS-CoV-2 variants, with no frozen cold chain, no mRNA, and no spike protein. The candidate completed a Phase 3 trial meeting all endpoints, targeting the general population needing COVID-19 booster vaccination.
• UB-311 (Alzheimer's Disease Vaccine) Active immunotherapy vaccine candidate targeting amyloid beta peptides for patients with mild Alzheimer's disease, designed to overcome immune tolerance and stimulate the patient's own antibody production. Phase 2a clinical trial completed with demonstrated safety, tolerability, immunogenicity, and efficacy.
• UB-312 (Parkinson's Disease Vaccine) Active immunotherapy vaccine candidate targeting pathological alpha-synuclein for patients with Parkinson's disease. Phase 1 trial demonstrated target engagement and immunogenicity, and the program produced the first Parkinson's candidate to reduce pathology as measured by seed amplification assay.
• VXX-401 (Anti-PCSK9 Cholesterol Vaccine) Anti-PCSK9 vaccine candidate designed to lower LDL cholesterol (LDL-C) for patients requiring cholesterol management via a preventive vaccination approach. Preclinical data published in the Journal of Lipid Research shows robust LDL-C reduction in cynomolgus monkeys with no safety signals observed.

Quantifiable outcome

• UB-312 is first Parkinson's candidate to reduce pathology as measured by seed amplification assay
• +2 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• University of Florida (UF) Center for Translational Research in Neurodegenerative Disease (CTRND)coreStrategic or Co-development Partner · 30 January 2024Research collaboration to support development of active immunotherapies for neurodegenerative diseases. Funded by a grant from the state of Florida. Aims to develop vaccines that could change the future of treatment by offering affordable and accessible therapeutic options.
• University of Central Florida (UCF)coreStrategic or Co-development Partner · 18 January 2024Collaboration to advance space medicine research funded by a grant from the State of Florida. Focuses on developing active immunotherapies to prevent and mitigate muscle and bone wasting related to long-term spaceflight, which share biological mechanisms with age-related diseases.

Scale indicators3 records

Recent moves7 records

Expansion highlights3 records

Direct peers

• Novavax: Recombinant protein subunit vaccine developer with COVID-19 and broader infectious disease pipeline. Direct peer in protein-based vaccine modality competing for similar booster and primary vaccine market, though with larger platform footprint.
• AC Immune: Clinical-stage biotech developing active immunotherapies and diagnostics targeting neurodegenerative diseases, including Alzheimer's and Parkinson's. Closest direct peer given overlapping indication focus on active immunization approaches to neuro targets.
• VBI Vaccines: Clinical-stage vaccine company developing virus-like particle (VLP) and enveloped VLP vaccines for infectious disease and immuno-oncology. Similar size, similar clinical-stage profile, and overlapping infectious-disease focus make it a strong comparability match.
• CureVac: mRNA-based vaccine developer with a focus on infectious disease including COVID-19, rabies, and other indications. Competes in the same vaccine modality space, with comparable clinical-stage pipeline profile for infectious-disease applications.

Broad incumbents

• Moderna: mRNA vaccine leader with approved COVID-19 vaccine and broad pipeline including infectious disease, oncology, and rare disease programs. Broad incumbent competing in the same indications (COVID-19, flu) but with much larger commercial reach and capital base.
• BioNTech: mRNA vaccine leader co-developing Comirnaty with Pfizer; also pursuing oncology and infectious disease programs. Competes with Vaxxinity in COVID-19 booster market and increasingly in infectious-disease mRNA applications.

Emerging players

• Dynavax Technologies: Commercial-stage vaccine company with HEPLISAV-B hepatitis B vaccine and CpG 1018 adjuvant used across multiple partner vaccine programs. Relevant peer given shared vaccine adjuvants/formulation focus and infectious-disease end markets.
• Vaxart: Clinical-stage company developing oral pill vaccines, including for COVID-19 and norovirus. Comparable in size and stage, with a different delivery modality but similar mission of differentiated vaccine formats targeting infectious disease.
• Imugene: Clinical-stage immuno-oncology and vaccine company developing B-cell immunotherapies and oncolytic virotherapies. Comparable as a small-cap peptide/immunotherapy platform company targeting novel vaccine-like modalities, though with an oncology focus.
• Provention Bio: Pre-commercial immunology company developing therapies for immune-mediated diseases, including a T1D delay therapy. Comparable in size and stage as a small clinical-stage immunology company that exited via acquisition, providing a relevant M&A-comparable precedent.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/vaxxinity

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds3 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vaxxinity